References
ACCP-SCCM Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864–874.
Astiz ME, Rackow EC: Septic shock. Lancet 1998, 351:1501–1505.
Davies HD, McGeer A, Schwartz B, et al.: Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med 1996, 335:547–554.
Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 1999, 340:207–214.
Ziegler EJ, Fisher CJ Jr, Sprung CL, et al.: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1991, 324:429–436.
Warren HS, Danner RL, Munford RS: Anti-endotoxin monoclonal antibodies. N Engl J Med 1992, 326:1153–1157.
McCloskey RV, Straube RC, Sanders C, et al.: Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1994, 121:1–5.
Derkx B, Wittes J, McCloskey R, et al.: Randomized, placebocontrolled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. Clin Infect Dis 1999, 28:770–777.
Bisno AL, Stevens DL: Streptococcal infections in skin and soft tissues. N Engl J Med 1996, 334:240–245.
Kaul R, McGeer A, Norrby-Teglund A, et al.: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. Clin Infect Dis 1999, 28:800–807.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tunkel, A.R. Septic shock and toxic shock: Do adjunctive therapies improve outcome?. Curr Infect Dis Rep 1, 215–217 (1999). https://doi.org/10.1007/s11908-999-0021-7
Issue Date:
DOI: https://doi.org/10.1007/s11908-999-0021-7